|Articles|December 4, 2007

Open letter from Genentech

Click here to read Genentech's open letter to ophthalmologists, outlining its reason for imposing restrictions on the use of Avastin.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.


Latest CME